CYT007-TNFQb is an active immunization therapy that aims at providing a novel treatment to people suffering from RA or psoriasis. The vaccine should allow for administration of low amounts of... The vaccine should allow for administration of low amounts of drug to individual patients (in the microgram range) and for convenient dosing schedules.
- Mechanism
- Curator reviewed
CYT007-TNFQb is designed to instruct the patient’s immune system to produce an anti-TNF-α antibody response. The induced antibodies aim to bind and neutrolize soluble TNF-α in order to inhibit its inflammatory activity. That way, the subsequent inflammatory process should be slowed down and the deterioration of skin or other tissues reduced.
- Primary indication
- Investigated for use/treatment in psoriasis and psoriatic disorders.Curator reviewed
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with CYT007-TNFQb, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account